ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Interestingly, treatment of CML patient-derived bone marrow cells with a combination of cyclopamine and the Abl inhibitor, Nilotinib, in vitro, reduced the number of colony-forming units by more than 80%.